Latest stories on LABT
LABT’s Nu-3 Demonstrates High Barrier to Resistance in Addressing Antibiotic-Resistant Bacteria
July 22, 2026
MarketChameleon67 · bullishproduct/pr
Why Is Penny Stock Lakewood-Amedex Biotherapeutics (LABT) Up Today?
TipRanks63 · neutralproduct/pr
LABT’s Nu-3 Candidate Shows High Barrier to Antibiotic Resistance—A Promising Step for Combating Superbugs
July 22, 2026
MarketChameleon73 · bullishproduct/pr
Lakewood-Amedex Biotherapeutics Inc. (LABT) files 8-K
SEC 8-K50 · neutralgeneral
Lakewood-Amedex Biotherapeutics Inc. (LABT) files 8-K
SEC 8-K50 · neutralgeneral
Lakewood-Amedex Biotherapeutics to Present at Life Sciences Virtual Investor Forum
PR Newswire56 · neutralgeneral
Lakewood-Amedex Expands Global IP Portfolio for Lead Candidate, Nu-3, Targeting Infected Diabetic Foot Ulcers
PR Newswire63 · neutralproduct/pr
Lakewood-Amedex’s Nu-3 Achieves Key Milestones Ahead of Phase 2 Trials for Diabetic Foot Ulcers
MarketChameleon67 · bullishproduct/pr
Lakewood-Amedex Biotherapeutics Announces Agreement with PERI to Serve as CRO for Phase 2 Clinical Trial of Nu-3
PR Newswire59 · neutralgeneral